Navigation Links
Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call
Date:7/30/2009

SEATTLE, July 30 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for its second quarter and six months ended June 30, 2009, after the close of market on Aug. 6, 2009. The company's earnings conference call will take place Aug. 6, 2009 at 2 p.m. Pacific Time, 5 p.m. Eastern Time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

The live event will be available for viewing on Trubion's website at http://investors.trubion.com.

Second Quarter and First Half 2009 Earnings Conference Call: 2 p.m. PDT / 5 p.m. EDT, Aug. 6, 2009

Trubion will host a conference call and webcast to discuss its second quarter and first half 2009 financial results. The call will be held Aug. 6 at 2 p.m. PDT (5 p.m. EDT). The live event will be available on Trubion's website at http://investors.trubion.com/events.cfm, or by calling 1 (719) 325-4854 or 1 (877) 440-5785. A replay of the discussion will be available beginning the evening of Aug. 6 on Trubion's website or by calling 1 (719) 457-0820 or 1 (888) 203-1112, and entering 9291496. The telephone replay will be available until midnight EDT, Thursday, Aug. 13, 2009.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
4. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
5. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
6. Trubion Announces Presentations at April/May Investor Conferences
7. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
8. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
9. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
10. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
11. Trubion Announces Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (PRWEB) September 30, 2014 New applications ... arrangements that have evolved in nature over millennia are ... bioinspired materials for applications in biophotonics in the ... . The journal is published by SPIE, the international ... Library. Several of the peer-reviewed articles are accessible via ...
(Date:10/1/2014)... TeselaGen Biotechnology has received a ... their bioCAD/CAM software suite, which uses synthetic biology ... Business Innovation Research Phase II grant will be used ... from the Lawrence Berkeley National Laboratory. j5 was developed ... laboratory that develops alternative fuel technologies for the Department ...
(Date:10/1/2014)... -- Industry leaders from retail pharmacies ... the theme, ,Commercial Opportunities in the Era of Reform, ... Elsevier , a world-leading provider of scientific, technical ... gathering of some of the industry,s most prominent healthcare ... and in the future. The Elsevier Healthcare ...
(Date:9/30/2014)... in German . ... (TUM) have demonstrated a new kind of building block ... computer chips could be based on three-dimensional arrangements of ... technology of the semiconductor industry CMOS fabrication of ... and collaborators at the University of Notre Dame are ...
Breaking Biology Technology:Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3
... 1, 2011 MediVet-America today announced the opening ... provide technical support for in-clinic animal stem cell ... Cryogenic Banking Services, Autologous Conditional Serum Processing, and ... MediVet-America, the leading developer of stem ...
... about biology, the closer we get to being able to ... disease itself becomes. A new research finding showing ... and the common but serious medical condition known as fatty ... have learned that a mind-boggling multitude of different kinds of ...
... popular confidence trick known as "shell game," researchers at ... and shuffle "quantum-mechanical peas" microwave single photons ... In a paper published in the Jan. 30 ... the first demonstration of the coherent control of a ...
Cached Biology Technology:MediVet-America, Leading Animal Stem Cell Developer, Launches MediVet Lab Services 2Specific populations of gut bacteria linked to fatty liver 2Specific populations of gut bacteria linked to fatty liver 3Specific populations of gut bacteria linked to fatty liver 4UCSB physicists challenge classical world with quantum-mechanical implementation of 'shell game' 2
(Date:9/30/2014)... Health (NIH) awarded Lawrence Livermore National Laboratory (LLNL) ... system that will enable researchers to better understand ... scale. , LLNL,s grant-funded project is part of ... (Brain Research through Advancing Innovative Neurotechnologies) Initiative , ... of the human mind and uncover ways to ...
(Date:9/30/2014)... reports positive results of a phase 1 clinical ... lung cancer marked by rearrangement of the gene ROS1. ... non-small cell lung cancer testing positive for ROS1 gene ... complete responses and 33 partial responses. Median progression-free survival ... resume its growth after being slowed by treatment ...
(Date:9/30/2014)... it comes to using marijuana, new research, involving mice ... Journal of Leukocyte Biology , suggests ... that you should. That,s because a team of Italian ... do serious long-term damage to the immune system. This ... diseases, such as multiple sclerosis, inflammatory bowel disease and ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Adolescent exposure to thc may cause immune systems to go up in smoke 2
... to make someone say 'yes', coffee can help. ... the extent to which we can be persuaded, finds ... Psychology. , The Australian researchers from the University of ... likely to attend to, and agree with, persuasive arguments. ...
... Scientists have determined that decay-accelerating factor (DAF), a protein ... a receptor for the bacteria Helicobacter pylori. Blocking this ... risk of peptic ulcer disease or gastric cancer. The ... the May 12 issue of the Journal of Biological ...
... that degrades the body's collagen infrastructure has been shown to ... is stored in white adipose tissue, the primary energy depot ... by a University of Michigan team acts as a metabolic ... in place, which allows fat cells to expand beneath the ...
Cached Biology News:Stomach receptor for H. pylori discovered 2Expanding waistlines triggered by your genes 2
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
...
... used in conjuction with Annexin V-FITC to ... stages of apoptosis (Annexin V positive, PI ... stages of apoptosis or already dead (Annexin ... in the orange range of the spectrum ...
... were cultured in RPMI 1640 with 2 mM ... growth. In order to keep the antigens ... acetone-methanol. The cells are arrayed on a ... wells surface specifically treated to enhance cellular attachment ...
Biology Products: